Correlation Between Bright Minds and Telomir Pharmaceuticals,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Bright Minds and Telomir Pharmaceuticals, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bright Minds and Telomir Pharmaceuticals, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Bright Minds Biosciences and Telomir Pharmaceuticals, Common, you can compare the effects of market volatilities on Bright Minds and Telomir Pharmaceuticals, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bright Minds with a short position of Telomir Pharmaceuticals,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bright Minds and Telomir Pharmaceuticals,.

Diversification Opportunities for Bright Minds and Telomir Pharmaceuticals,

-0.69
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Bright and Telomir is -0.69. Overlapping area represents the amount of risk that can be diversified away by holding Bright Minds Biosciences and Telomir Pharmaceuticals, Commo in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Telomir Pharmaceuticals, and Bright Minds is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bright Minds Biosciences are associated (or correlated) with Telomir Pharmaceuticals,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Telomir Pharmaceuticals, has no effect on the direction of Bright Minds i.e., Bright Minds and Telomir Pharmaceuticals, go up and down completely randomly.

Pair Corralation between Bright Minds and Telomir Pharmaceuticals,

Given the investment horizon of 90 days Bright Minds Biosciences is expected to generate 16.41 times more return on investment than Telomir Pharmaceuticals,. However, Bright Minds is 16.41 times more volatile than Telomir Pharmaceuticals, Common. It trades about 0.15 of its potential returns per unit of risk. Telomir Pharmaceuticals, Common is currently generating about -0.03 per unit of risk. If you would invest  119.00  in Bright Minds Biosciences on September 22, 2024 and sell it today you would earn a total of  3,746  from holding Bright Minds Biosciences or generate 3147.9% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Bright Minds Biosciences  vs.  Telomir Pharmaceuticals, Commo

 Performance 
       Timeline  
Bright Minds Biosciences 

Risk-Adjusted Performance

11 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Bright Minds Biosciences are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, Bright Minds reported solid returns over the last few months and may actually be approaching a breakup point.
Telomir Pharmaceuticals, 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Telomir Pharmaceuticals, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Bright Minds and Telomir Pharmaceuticals, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Bright Minds and Telomir Pharmaceuticals,

The main advantage of trading using opposite Bright Minds and Telomir Pharmaceuticals, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bright Minds position performs unexpectedly, Telomir Pharmaceuticals, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telomir Pharmaceuticals, will offset losses from the drop in Telomir Pharmaceuticals,'s long position.
The idea behind Bright Minds Biosciences and Telomir Pharmaceuticals, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Other Complementary Tools

Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years